Stockreport

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Ikena Oncology, Inc.  (IKNA) 
PDF Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a sil [Read more]